Spotlight -

PBMI Innovators|

2026 State of Pharmacy survey results available now|

Our July 2026 issue

Biologics

Latest News

Latest Videos

Impact of an "Open" Market on Biosimilar Development

Impact of an "Open" Market on Biosimilar Development

Evidence-Based Recommendations and Safety Considerations Surrounding Biosimilars

Evidence-Based Recommendations and Safety Considerations Surrounding Biosimilars

Overview of Originator Biologics, Biosimilars, and Unbranded Biologics

Overview of Originator Biologics, Biosimilars, and Unbranded Biologics

Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars

Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars

Implications of Multiple Switching with Biologic Therapies

Implications of Multiple Switching with Biologic Therapies

Differentiating Between Unbranded Biologics and Biosimilars

Differentiating Between Unbranded Biologics and Biosimilars

Emphasizing Biologics Space as Payer Priority

Emphasizing Biologics Space as Payer Priority

Clinical Impacts of Biologics on Patient Quality of Care

Clinical Impacts of Biologics on Patient Quality of Care

Overview and Prevalence of Biologics

Overview and Prevalence of Biologics

CME Content

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

In-Person + Virtual Event

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

27th Annual International Lung Cancer Congress®

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

2 Sessions are Available!

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

In-Person + Virtual Event

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

October 26, 2026

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS

More News

Image credit: © lexiconimage stock.adobe.com

FDA Approves Simlandi, Third Interchangeable Humira Biosimilar

ByPeter Wehrwein, Managing Editor

February 24th 2024

At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.

2024 Formulary Moves

ByDenise Myshko

January 5th 2024

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

Biosimilars are Ascendant

ByTony Hagen,Peter Wehrwein, Managing Editor

December 19th 2023

Acceptance is greater in oncology than in other specialties.

Biosimilar K-Cast - "Overcoming Challenges Associated with Biosimilars"

Overcoming Challenges Associated with Biosimilars

October 11th 2023

Challenges with biosimilars and unbranded biologics are discussed and how can they be improved.

Trending on Managed Healthcare Executive

Payer Implications and Final Takeaways from the BE BOLD Trial

A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy

The biosimilars market is projected to nearly double — here's where the growth is coming from

Journavx helped most patients avoid opioids after surgery, a recent study found

Endometriosis increases the risk of Type 2 diabetes